EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy

Xiaoping Li, Parham Jabbarzadeh Kaboli, Ghazaal Roozitalab, Shanli Salahi, Hongbo Qian, Xinyi Zhang, Keda Chen, Saber Imani

Cellular Oncology · 2026

DOI: 10.1007/s13402-026-01199-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cellular Oncology, 2026. Verfasst von Xiaoping Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Immunotherapy, Cancer Vaccines, Precision Medicine. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Shuren University Basic Scientific Research Special Funds, Zhejiang Health Information Association Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoantigen mRNA vaccines have progressed from experimental constructs to clinically evaluated immunotherapies grounded in tumor genomics and modular RNA engineering. By encoding tumor-restricted antigens, these platforms aim to induce targeted T-cell responses while minimizing off-target toxicity. Early clinical studies, particularly in melanoma and non-small cell lung cancer, demonstrate that personalized and hybrid vaccine strategies can expand tumor-reactive T-cell clones and improve recurrence-free outcomes when combined with immune checkpoint blockade. However, challenges including manufacturing timelines, HLA diversity, tumor heterogeneity, and immune editing limit broad implementation. Recent advances in antigen prioritization algorithms, transcript design, and delivery platforms have improved translational feasibility and reduced production variability. Shared and off-the-shelf approaches targeting recurrent driver mutations offer scalable alternatives, while adaptive strategies incorporating ctDNA monitoring raise the possibility of dynamic vaccine updating during treatment. Integration with immune-modulating therapies and rational clinical positioning, particularly in adjuvant and minimal residual disease settings, are likely to define near-term success. Collectively, neoantigen mRNA vaccination represents a flexible therapeutic framework rather than a single platform. Its long-term impact will depend on aligning molecular engineering, immune calibration, manufacturing scalability, and regulatory adaptation to achieve durable clinical.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmImmunotherapyCancer VaccinesPrecision MedicineRNA, MessengerNeoplasmsmRNA VaccinesHumansAnimals

Stichwörter der Autor:innen

Antigen presentation engineeringBiomaterials-based deliveryImmunoengineeringNeoantigen mRNA vaccinesThermostable formulationsTranslational manufacturing

Substanzen

Antigens, NeoplasmCancer VaccinesRNA, MessengermRNA Vaccines

Autor:innen und Institutionen

  • Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
  • Research & Innovation Lab, OncoVanguard Media, Texas Medical Center, Houston, TX, 77025, USA.
  • Department of Metallurgical and Materials Engineering, Faculty of Technology, University of Gazi, Ankara, 06500, Turkey.
  • School of Health in Social Science, University of Edinburgh, Edinburgh, UK.
  • Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China. saber.imani@zjsru.edu.cn.

Förderung

  • Zhejiang Shuren University Basic Scientific Research Special Funds
  • Zhejiang Health Information Association Research Program

Zitieren

APA

Li, X., Jabbarzadeh Kaboli, P., Roozitalab, G., Salahi, S., Qian, H., Zhang, X., Chen, K., & Imani, S. (2026). Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy. Cellular Oncology. https://doi.org/10.1007/s13402-026-01199-1

Vancouver

Li X, Jabbarzadeh Kaboli P, Roozitalab G, Salahi S, Qian H, Zhang X, et al. Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy. Cellular Oncology. 2026. doi:10.1007/s13402-026-01199-1

BibTeX
@article{Li2026,
  author = {Li, Xiaoping and Jabbarzadeh Kaboli, Parham and Roozitalab, Ghazaal and Salahi, Shanli and Qian, Hongbo and Zhang, Xinyi and Chen, Keda and Imani, Saber},
  title = {Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy},
  journal = {Cellular Oncology},
  year = {2026},
  doi = {10.1007/s13402-026-01199-1}
}
Kostenlos starten →